Recordati Lifts Treasury Stake With Latest Share Buy-Back Tranche

The latest update is out from Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ).

Recordati has reported progress on its ongoing share buy-back program authorized in 2025 to service existing and future stock option, performance share and other share-based incentive plans for group management. Between 9 and 13 March 2026 the company repurchased 126,164 ordinary shares on the EXM at a weighted average price of €46.3054, bringing its treasury stock to 5,534,400 shares, or 2.646% of current share capital.

The latest tranche of buy-backs underscores Recordati’s continued use of treasury shares as a tool to support long-term incentive schemes and align management interests with shareholders. By incrementally increasing its treasury share position, the group maintains flexibility in capital management while limiting dilution from equity-based remuneration, a practice that can influence investor perception of governance and capital allocation discipline.

The most recent analyst rating on (IT:REC) stock is a Buy with a EUR57.50 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.

More about Recordati Industria Chimica e Farmaceutica SPA

Recordati Industria Chimica e Farmaceutica is an international pharmaceutical group listed on the Italian Stock Exchange, with origins in a family-run pharmacy in Northern Italy in the 1920s. The company develops and supplies treatments in specialty and primary care as well as rare diseases, operating integrated clinical development, manufacturing and commercialization across roughly 150 countries in EMEA, the Americas and APAC.

Average Trading Volume: 335,006

Technical Sentiment Signal: Hold

Current Market Cap: €9.28B

Learn more about REC stock on TipRanks’ Stock Analysis page.